Pegfilgrastim biosimilar (Adello Biologics)

培非格司亭生物类似药 (Adello Biologics)

Report date: 2026/02/25 20:02:36

Base Information

Drug NamePegfilgrastim biosimilar (Adello Biologics)
Drug Alias NamePegfilgrastim-PBBK培非拉司亭生物仿制药非格司亭生物仿制药long-acting G-CSF biosimilar培非司亭生物仿制药 +[12] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Global Approved IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/02/25
Country/TerritoryUnited StatesJordan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAdello Biologics Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdello Biologics LlcKashiv BioSciences LLC
Inactive CompaniesN/A
Active IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AA13
Related LinksN/A